Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Young Rok Choi 1 Article
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis
Hyunjin Park, Hyejung Lee, An Na Seo, Jai Young Cho, Young Rok Choi, Yoo-Seok Yoon, Ho-Seong Han, Young Nyun Park, Haeryoung Kim
J Pathol Transl Med. 2015;49(5):373-381.   Published online August 10, 2015
DOI: https://doi.org/10.4132/jptm.2015.07.09
  • 9,801 View
  • 76 Download
  • 21 Web of Science
  • 20 Crossref
AbstractAbstract PDF
Background
There is increasing interest in hepatocellular carcinomas (HCC) expressing “stemness”-related markers, as they have been associated with aggressive behavior and poor prognosis. In this study, we investigated the usefulness of Sal-like protein 4 (SALL4), a recently proposed candidate marker of “stemness.” Methods: Immunohistochemical stains were performed for SALL4, K19, and epithelial cellular adhesion molecule (EpCAM) on tissue microarrays constructed from 190 surgically resected HCCs, and the results were correlated with the clinicopathological features and patient survival data. Results: Nuclear SALL4 expression was observed in 39/190 HCCs (20.5%), while K19 and EpCAM were expressed in 30 (15.9%) and 92 (48.7%) HCCs, respectively. The nuclear expression was generally weak, punctate or clumped. SALL4 expression was significantly associated with a poor overall survival compared to SALL4-negative HCCs (p = .014) compared to SALL4-negative HCCs. On multivariate analysis adjusted for tumor size, multiplicity, vascular invasion, and pathological tumor stage, SALL4 remained as a significant independent predictor of decreased overall survival (p= .004). SALL4 expression was positively correlated with EpCAM expression (p = .013) but not with K19 expression. HCCs that expressed both SALL4 and EpCAM were associated with significantly decreased overall survival, compared to those cases which were negative for both of these markers (p = .031). Conclusions: Although SALL4 expression was not significantly correlated with other clinicopathological parameters suggestive of tumor aggressiveness, SALL4 expression was an independent predictor of poor overall survival in human HCCs, and was also positively correlated with EpCAM expression.

Citations

Citations to this article as recorded by  
  • Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
    Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
    Annals of Hepatology.2024; 29(1): 101153.     CrossRef
  • Research progress and prospects of AFP-positive gastric cancer
    Long Zhao, Changjiang Yang, Yilin Lin, Shan Wang, Yingjiang Ye, Zhanlong Shen
    Foregut Surgery.2022; 2(1): 29.     CrossRef
  • SALL4 and microRNA: The Role of Let-7
    Jun Liu, Madeline A. Sauer, Shaza G. Hussein, Junyu Yang, Daniel G. Tenen, Li Chai
    Genes.2021; 12(9): 1301.     CrossRef
  • Hepatoid Teratoma, Hepatoid Yolk Sac Tumor, and Hepatocellular Carcinoma
    Khaleel I. Al-Obaidy, Sean R. Williamson, Nathan Shelman, Muhammad T. Idrees, Thomas M. Ulbright
    American Journal of Surgical Pathology.2021; 45(1): 127.     CrossRef
  • Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy
    Junyu Yang, Chong Gao, Miao Liu, Yao-Chung Liu, Junsu Kwon, Jun Qi, Xi Tian, Alicia Stein, Yanjing V. Liu, Nikki R. Kong, Yue Wu, Shenyi Yin, Jianzhong Xi, Zhiyuan Chen, Kalpana Kumari, Hannan Wong, Hongbo Luo, Leslie E. Silberstein, Julie A.I. Thoms, Ash
    Cancer Research.2021; 81(23): 6018.     CrossRef
  • Lipoprotein‐Like Nanoparticle Carrying Small Interfering RNA Against Spalt‐Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden
    William Cruz, Huang Huang, Brian Barber, Elisa Pasini, Lili Ding, Gang Zheng, Juan Chen, Mamatha Bhat
    Hepatology Communications.2020; 4(5): 769.     CrossRef
  • Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features
    Yakun Wang, Li Sun, Zhongwu Li, Jing Gao, Sai Ge, Cheng Zhang, Jiajia Yuan, Xicheng Wang, Jian Li, Zhihao Lu, Jifang Gong, Ming Lu, Jun Zhou, Zhi Peng, Lin Shen, Xiaotian Zhang
    Gastric Cancer.2019; 22(6): 1183.     CrossRef
  • Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens
    Shuyue Ren, William Klump
    Archives of Pathology & Laboratory Medicine.2019; 143(6): 677.     CrossRef
  • The pluripotency network in colorectal cancer pathogenesis and prognosis: an update
    Ioannis A Voutsadakis
    Biomarkers in Medicine.2018; 12(6): 653.     CrossRef
  • Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies
    Nuozhou Wang, Shanshan Wang, Ming-Yue Li, Bao-guang Hu, Li-ping Liu, Sheng-li Yang, Shucai Yang, Zhongqin Gong, Paul B. S. Lai, George G. Chen
    Therapeutic Advances in Medical Oncology.2018; 10: 175883591881628.     CrossRef
  • DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection
    H Fan, Z Cui, H Zhang, S K Mani, A Diab, L Lefrancois, N Fares, P Merle, O Andrisani
    Oncogene.2017; 36(17): 2435.     CrossRef
  • Higher expression of SALL4 predicts poor cancer prognosis: A meta-analysis
    Hongyu Shen, Liangpeng Li, Dandan Wang, Sujin Yang, Xiu Chen, Siying Zhou, Shanliang Zhong, Jianhua Zhao, Jinhai Tang
    Cancer Biomarkers.2017; 19(4): 365.     CrossRef
  • SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway
    Chuanjin Liu, Haibin Wu, Yanyan Li, Liang Shen, Renchun Yu, Hongwei Yin, Ting Sun, Chunming Sun, Youxin Zhou, Ziwei Du
    Journal of Neuro-Oncology.2017; 135(2): 263.     CrossRef
  • Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
    Germana Castelli, Elvira Pelosi, Ugo Testa
    Cancers.2017; 9(9): 127.     CrossRef
  • Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis
    Lorenzo Nicolè, Tiziana Sanavia, Nicola Veronese, Rocco Cappellesso, Claudio Luchini, Paolo Dabrilli, Ambrogio Fassina
    Oncotarget.2017; 8(14): 22968.     CrossRef
  • SALL4, the missing link between stem cells, development and cancer
    Hiro Tatetsu, Nikki R. Kong, Gao Chong, Giovanni Amabile, Daniel G. Tenen, Li Chai
    Gene.2016; 584(2): 111.     CrossRef
  • A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer
    Soo Jeong Nam, Hyun Yang Yeo, Hee Jin Chang, Bo Hyun Kim, Eun Kyung Hong, Joong-Won Park
    Cancer Research and Treatment.2016; 48(4): 1229.     CrossRef
  • Functional and clinical significance of SALL4 in breast cancer
    Ebubekir Dirican, Mustafa Akkiprik
    Tumor Biology.2016; 37(9): 11701.     CrossRef
  • MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression
    Qinggang Tian, Yao Xiao, Yanting Wu, Yun Liu, Zhiqing Song, Wenfeng Gao, Jing Zhang, Jingling Yang, Yuguo Zhang, Tuankui Guo, Furong Dai, Zhigang Sun
    International Journal of Molecular Medicine.2016; 38(5): 1587.     CrossRef
  • Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta-analysis of individual studies
    Ji Cheng, Jinbo Gao, Xiaoming Shuai, Kaixiong Tao
    Oncotarget.2016; 7(17): 24314.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine